Prostate Cancer - Results from #1840

Prostate Cancer, Race, and Health Disparity: What We Know. November 17, 2023

A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. November 17, 2023

Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. November 17, 2023

68Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional study. November 17, 2023

Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis. November 17, 2023

Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI. November 16, 2023

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. November 16, 2023

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. November 16, 2023

Genetic and biological drivers of prostate cancer disparities in Black men. November 16, 2023

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. November 16, 2023

Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. November 15, 2023

Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia. November 15, 2023

Robot-Assisted Radical Prostatectomy in Renal Transplant Recipients: A Systematic Review. November 15, 2023

MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease. November 15, 2023

Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men. November 15, 2023

Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. November 14, 2023

National long-term survival estimates after radical prostatectomy for prostate cancer. November 14, 2023

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. November 14, 2023

Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression. November 14, 2023

Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation. November 14, 2023

Page 93 of 1438